Ann: Clinical Trial for BodyGuard Technology, page-35

So not only is non-NSAID development still in the mix, the more immediate pain relief already shown by laboratory studies to be very effective at delivering IBU through the skin is going through a double blind clinical trial to test efficacy..
The end result most probably being manufactured &  marketed as a safer more effective use of several NSAID products currently available..
The other plus is the pending trials and use for other drugs not currently well served by traditional drug-in-adhesive product approaches.

VLA is a good example of a similar product undergoing testing that will still take some years before it gets to market. It is as an alternative cancer treatment but the share price is rising as the testing continues to deliver positive results.

I expect the same appreciation in OBJ sher price after the NSAID tests at Curtin are underway and results (hopefully backing up laboratory tests) are received. I believe it will be a much quicker path to commercialisation than other products.

from the release...

OBJ’s Lubricen formulation is directed at the non-NSAID markets and management is working with several companies to distribute BodyGuard with this formulation. Undertaking the IBU clinical trial opens up a broader market where immediate pain relief is required, an area in which many of the multinational pharmaceutical companies operate.

With the aid of its USA pharmaceutical partner, OBJ has succeeded in developing a new topical formulation and array combination that has shown, in laboratory studies, to be very effective at delivering IBU through the skin. The Curtin study, with the support of the Innovation Connections Grant Scheme, will test the new formulation and format in a double blind clinical efficacy study.

A successful outcome will not only support the OBJ technology as a suitable IBU delivery development platform for its partners, but will also demonstrate the power of the OBJ polymer hydro-array technology for use with many other drugs not currently well served

SK60